Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Joshua Boyce, M.D
Brigham and Womens Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama
Birmingham, Alabama, United States
- Brigham and Womens Hospital
Boston, Massachusetts, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Columbia University
New York, New York, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- Temple University
Philadelphia, Pennsylvania, United States
- University of Wisconsin
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2010
- Primary completion
- 31 Aug 2015
- Completion
- 31 Aug 2016
- Last update posted
- 19 May 2017
- Registered enrollment
- 176
- Registry id
- NCT01097694
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.